Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Dexcom (DXCM)

Dexcom Q3 revenue rises 22% to $1.209 billion; raises 2025 revenue guidance

Positive Impact 4 of 5 earnings Written later

Dexcom reported third-quarter 2025 results on October 30, 2025. Revenue rose 22% year over year to $1.209 billion, and GAAP net income was $283.8 million, or $0.70 per diluted share, compared with $0.34 a year earlier. The company raised its full-year 2025 revenue guidance to $4.630-$4.650 billion and updated its margin guidance, which matters to shareholders because the company's headline revenue and profit measures improved.

Key points

  • Revenue of $1.209 billion, up 22% from $994.2 million in Q3 2024; organic revenue growth was 20%
  • GAAP net income of $283.8 million, or $0.70 per diluted share, versus $134.6 million, or $0.34, a year earlier
  • 2025 revenue guidance raised to $4.630-$4.650 billion, approximately 15% growth
  • Cash, cash equivalents and marketable securities of $3.32 billion as of September 30, 2025; Jake Leach is president and interim CEO

The filing

CompanyDexcom (DXCM)
Form8-K, current report
Filed with the SECOct 30, 2025, 4:02 PM ET
Accession number0001093557-25-000278

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.